Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Carcinoma
NCT05165355
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
90
Enrollment
OTHER
Sponsor class
Conditions
NSCLC
EGF-R Positive Non-Small Cell Lung Cancer
Interventions
DRUG:
Furmonertinib
Sponsor
Tongji University